1035 Cambridge Street
Suite 18A
Cambridge, MA 02141
United States
212 582 1199
https://eternatx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 8
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Ms. Sandra M. Gurrola | Principal Financial & Accounting Officer and Senior VP of Finance | 305,88k | S.O. | 1967 |
Mr. Sanjeev Luther | CEO, President & Director | S.O. | S.O. | 1962 |
Ms. Dorothy J. Clarke | General Counsel & Director | S.O. | S.O. | 1966 |
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
L’ISS Governance QualityScore de Eterna Therapeutics Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..